 |
|
|
 |
|
|
 |
|
|
Pittsboro, North Carolina
Jan Turek, President/CEO |
|
Biolex Therapeutics, is a private, venture capital-backed biopharmaceutical company located in the Research Triangle region of North Carolina. Biolex Therapeutics has commercially developed the transformational LEX SystemTM for the expression of human therapeutic proteins.
- The LEX SystemTM is a fast and flexible gene manipulation system, resulting in high protein expression from the aquatic plant Lemna. The LEX SystemTM uniquely combines the most desired qualities (clonal replication, fast growth, high protein content, secretion of the target protein into the media, a contained and controlled environment) of mammalian cell culture, the current gold standard among existing expression systems, with the most sought after characteristics (speed of scale-up, significantly reduced capital requirement, low operating costs) in next generation systems.
- All the human therapeutic proteins Biolex Therapeutics has attempted (including: a peptide; multimeric proteins; alpha interferon and other cytokines; and monoclonal antibodies) have been expressed successfully in the LEX SystemTM and each of the proteins characterized to date has been demonstrated to have the predicted composition, desired physical structure and correct biological activity. Biolex Therapeutics believes these results provide compelling proof-of-concept.
- Biolex Therapeutics intends to aggressively form collaborations with, and make the LEX SystemTM the preferred protein expression system for, pharmaceutical and biotechnology companies. In parallel, Biolex Therapeutics intends to source and develop its own proprietary proteins ("Biolex Proteins"). Biolex Therapeutics currently has four top-tier corporate collaborations for seven different proteins. Biolex Therapeutics' corporate partners include Bayer Corporation (2 proteins), Centocor, Inc. (3 proteins), Debiopharm S.A., and a major pharma company. Alpha interferon is in development as the first Biolex Protein, with IND submission targeted for 2004.
www.biolex.com
|
|
|
|
